Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Hold" by Brokerages

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty-three ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $53.58.

A number of research firms recently issued reports on MRNA. UBS Group lowered their target price on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Barclays cut their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a report on Friday, May 2nd. Royal Bank of Canada lowered their target price on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Evercore ISI dropped their price target on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Finally, Bank of America decreased their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th.

Moderna Trading Down 4.2%

Shares of NASDAQ:MRNA opened at $26.12 on Friday. Moderna has a 1-year low of $23.15 and a 1-year high of $158.82. The stock has a market capitalization of $10.10 billion, a P/E ratio of -2.81 and a beta of 1.86. The business has a 50-day moving average price of $26.11 and a two-hundred day moving average price of $33.57.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm's quarterly revenue was down 35.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.07) EPS. As a group, equities analysts predict that Moderna will post -9.61 EPS for the current year.

Hedge Funds Weigh In On Moderna

Several institutional investors have recently made changes to their positions in MRNA. Norges Bank purchased a new position in Moderna during the fourth quarter valued at $163,833,000. Voloridge Investment Management LLC lifted its stake in shares of Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock worth $107,727,000 after buying an additional 1,996,003 shares in the last quarter. FMR LLC raised its holdings in Moderna by 7.4% in the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after acquiring an additional 1,282,469 shares during the last quarter. Pictet Asset Management Holding SA grew its position in shares of Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after purchasing an additional 1,113,455 shares in the last quarter. Finally, SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new stake in Moderna in the 1st quarter valued at $28,350,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.